DealApr 21, 2026
Deal — Eli Lilly’s Kelonia Therapeutics acquisition seen as strategic bet on next-generation CAR-T: analysts▸
medium impact
DealApr 20, 2026
Deal — Eli Lilly to Strengthen Cancer Treatment Portfolio With $7 Billion Deal for Kelonia▸
medium impact
DealApr 19, 2026
Deal — Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says▸
medium impact
Data +Apr 18, 2026
Positive data — Foundayo Trial Results Recast Eli Lilly Story On GLP1 Safety And Growth▸
high impact
DealApr 16, 2026
Deal — Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson▸
medium impact
Data +Apr 16, 2026
Positive data — ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and over…▸
high impact
DealApr 15, 2026
Deal — Lilly to acquire CrossBridge Bio for up to $300m▸
medium impact
ApprovalApr 15, 2026
FDA approval — Lilly Stock Dips on FDA Request for More Foundayo Safety Data. Is the Market Reaction Overblown?▸
high impact
DealApr 14, 2026
Deal — Eli Lilly and Company entered into a definitive agreement to acquire CrossBridge Bio, Inc. for $300 million.▸
medium impact
Data +Apr 14, 2026
Positive data — Eli Lilly Broadens Oncology Portfolio As Investors Reassess Valuation Potential▸
high impact
Data +Apr 13, 2026
Positive data — Eli Lilly And Company Announces Positive Phase 3 Results For Jaypirca (Pirtobrutinib) In Previously Treated CLL/SLL▸
high impact
ApprovalApr 11, 2026
FDA approval — Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect▸
high impact
ApprovalApr 09, 2026
FDA approval — Eli Lilly Just Launched Its $149 Obesity Pill▸
high impact